Ensure your baby's health and safety with NUKOVAX 13, a pneumococcal conjugate vaccine developed in China, procured by G.C. Chemie Pharmie Ltd, and remarketed by Lupin. Trusted by healthcare professionals, NUKOVAX 13 offers robust protection against pneumococcal disease, which can lead to severe infections such as pneumonia, meningitis, and bloodstream infections.
Key Benefits
- Comprehensive Protection: Safeguards infants against 13 strains of pneumococcal bacteria
- Clinically Proven: Supported by rigorous clinical trials and approved by global health authorities
- Safe and Effective: Known for its high efficacy and low incidence of side effects
- Essential for Infants: Recommended only for babies under 1 year of age to provide early and effective protection
- Meets Pediatric Guidelines: Complies with immunization schedules for infants as per global health recommendations
🧬 Active Compound
The active ingredient in NUKOVAX 13 is a pneumococcal polysaccharide conjugate vaccine. It contains purified capsular polysaccharides from 13 strains of Streptococcus pneumoniae (pneumococcus), conjugated to a tetanus toxoid (TT) protein.
🔹 Polysaccharides
Derived from the capsules of 13 different serotypes of Streptococcus pneumoniae. These serotypes are: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
🔹 Carrier Protein (Tetanus Toxoid - TT)
A highly purified and non-toxic form of the tetanus protein, used to enhance the immune system's response to the polysaccharides. This conjugation ensures a strong and long-lasting immune response, particularly in infants under 1 year of age.
1 3 4 5 6A 6B 7F 9V 14 18C 19A 19F 23F
📅 Schedule and Dosage
Vaccination Protocol
📌 Age Group: Only for infants under 1 year of age
📌 Dosage: 3 doses (0.5 mL each)
📌 Timing Options:
Schedule Option 1
- Dose 1: At 2 months of age
- Dose 2: At 4 months of age
- Dose 3: At 6 months of age
Schedule Option 2
- Dose 1: At 6 weeks of age
- Dose 2: At 10 weeks of age
- Dose 3: At 14 weeks of age
💉 What to Expect
💉 Common Side Effects
Mild reactions are normal and typically resolve within 1-2 days:
- Redness or swelling at the injection site
- Low-grade fever
- Fussiness or irritability
- Temporary loss of appetite
- Drowsiness
🩹 Post-Vaccination Care
- Use a cool compress on the injection site to alleviate any discomfort
- Give plenty of fluids and comfort
- Monitor for any unusual reactions
- Contact your pediatrician if fever persists beyond 48 hours or if you notice severe reactions
🌟 Why Choose NUKOVAX 13?
✅ Expert Recommendation
Endorsed by pediatricians worldwide for its reliability and effectiveness in protecting infants from pneumococcal disease.
🧬 Innovative Technology
Uses tetanus toxoid (TT) as a carrier protein, ensuring a robust immune response even in very young infants.
🌍 Global Collaboration
Developed in collaboration with a trusted source in China, adhering to international quality standards.
😌 Peace of Mind
Provides parents with confidence in their baby's health and well-being, protecting against life-threatening infections.
🛡️ Understanding Pneumococcal Disease
Pneumococcal disease is caused by Streptococcus pneumoniae bacteria and can lead to serious, potentially life-threatening infections:
Infections Prevented by NUKOVAX 13
- Pneumonia: Lung infection causing difficulty breathing, fever, and chest pain
- Meningitis: Brain and spinal cord infection that can cause permanent brain damage or death
- Bacteremia/Sepsis: Bloodstream infection leading to organ failure and shock
- Otitis Media: Middle ear infections causing pain and potential hearing loss
Infants and young children are at highest risk because their immune systems are still developing. NUKOVAX 13 provides crucial early protection during this vulnerable period.
🏫 School & Daycare Compliance
✓ Meets Vaccination Requirements
NUKOVAX 13 meets vaccination requirements for schools and daycare centers worldwide. Completing the 3-dose series ensures your child is protected and compliant with immunization standards, giving you peace of mind as they begin their educational journey.
✓ Give Your Baby the Best Start in Life
NUKOVAX 13 is a vaccine designed exclusively for infants under 1 year of age to provide early and effective protection against pneumococcal disease. With its proven safety profile, clinical effectiveness, and global quality standards, NUKOVAX 13 combines advanced technology, international collaboration, and trusted expertise to ensure your child's health and safety.
